Skip to main content

Table 2 NGS-based molecular alterations in BRAF -positive melanoma responders

From: Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance

Case no.

BRAFmutation

Type of targeted drug

Treatment start date

Best response (%)

TTF (months)a

Sampling date; time from treatmentb

Molecular analysis by NGS

Mutations

Amplifications/deletions

Truncations

1

V600E

BRAF inhibitor

9/17/2009

CR (−100)

28.7+

5/1/2009; −4 months

BRAF (V600E)

None

None

2

V600E

BRAF inhibitor

10/7/2009

CR (−100)

27.4+

1/22/2009; −9 months

BRAF (V600E); BRAF (T599S)

AURKA amplification; BRAF amplification

None

T599S

3

V600E

BRAF inhibitor

1/27/2010

CR (−100)

23.6+

8/19/2005; −53 months

Nonec

None

None

4

V600E

BRAF + MEK inhibitor

11/11/2010

PR (−34)

11.2

5/17/2011; +6 months

APC (R1171H); BRAF (V600E); NRAS (Q61R)

PTEN deletion

RB1 truncation

5

V600E

BRAF inhibitor

6/17/2009

PR (−38)

7.9

12/2/2009; +6 months

BRAF (V600E)

CDKN2A deletion; CDKN2B deletion; PAX5 deletion

None

      

3/23/2010; +9 months

BRAF (V600E)

CDKN2A deletion; CDKN2B deletion; PAX5 deletion

NF1 truncation

      

8/24/2011; +26 months

None

None

None

6

V600E

MEK inhibitor

4/1/2010

PR (−53)

7.0

9/17/2007; −31 months

BRAF (V600E)

None

None

7

V600E

BRAF inhibitor

1/12/2010

PR (−48)

5.7

11/5/2009; −2 months

BRAF (V600E)

MITF amplification

None

8

V600E

BRAF + MEK inhibitor

9/3/2010

CR (−100)

5.6

4/7/2009; −17 months

BRAF (V600E); NF1 (R 440*)d

None

None

9

V600E

BRAF inhibitor

1/27/2010

PR (−75)

4.2

11/11/2009; −2 months

BRAF (V600E)

BRAF amplification; MET amplification; CDKN2A deletion; CDKN2B deletion

ATM truncation

10

V600E

BRAF inhibitor

4/15/2010

PR (−54)

3.0

12/11/2009; −4 months

BRAF (V600E)

MYC amplification; CDKN2A deletion

None

  1. a ‘+’ = continuing on the study when data was censored.
  2. b ‘ + ’ = number of months biopsy was taken after treatment; '-' = number of months biopsy preceded treatment.
  3. c = tissue sample obtained on 10/29/2008 was BRAF mutation-positive (V600E) by single PCR assay (case #3).
  4. d = tissue sample obtained from a progressive hepatic lesion on 12/27/2010 had an NRAS mutation (Q61K) in codon 61 by single PCR assay (case #8).
  5. Abbreviations:CR Complete response, NGS Next generation sequencing, PR Partial response, TTF Time to treatment failure.